Nancy Jean Barnabei
Keine laufenden Positionen mehr
Karriereverlauf von Nancy Jean Barnabei
Ehemalige bekannte Positionen von Nancy Jean Barnabei
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
REBUS HOLDINGS, INC. | Comptroller/Controller/Auditor | 21.08.2012 | 30.06.2013 |
Finanzdirektor/CFO | 21.08.2012 | 30.06.2013 | |
Treasurer | 21.08.2012 | 30.06.2013 | |
Corridor Pharmaceuticals, Inc.
Corridor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corridor Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. The company was founded on February 1, 2008 and is headquartered in Lutherville, MD | Finanzdirektor/CFO | 01.01.2011 | 01.01.2011 |
Immune Control, Inc.
Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Finanzdirektor/CFO | 01.02.2008 | 01.01.2010 |
Locus Pharmaceuticals, Inc.
Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Finanzdirektor/CFO | 01.01.2002 | 01.01.2004 |
Treasurer | 01.01.2002 | 01.01.2004 | |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Comptroller/Controller/Auditor | - | - |
Ausbildung von Nancy Jean Barnabei
Northeastern University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Director of Finance/CFO | 4 |
Treasurer | 2 |
Comptroller/Controller/Auditor | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
REBUS HOLDINGS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Immune Control, Inc.
Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Health Technology |
Locus Pharmaceuticals, Inc.
Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Health Technology |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Corridor Pharmaceuticals, Inc.
Corridor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corridor Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. The company was founded on February 1, 2008 and is headquartered in Lutherville, MD | Health Technology |
- Börse
- Insiders
- Nancy Jean Barnabei
- Erfahrung